2021年3期
刊物介紹
本刊主要是及時(shí)報(bào)道我國(guó)在腫瘤防治研究領(lǐng)域包括癌癥基礎(chǔ)理論研究和癌癥預(yù)防、臨床治療研究方面的新進(jìn)展、新成果，內(nèi)容涉及腫瘤病因?qū)W與滸病學(xué)，實(shí)驗(yàn)?zāi)[瘤學(xué)、腫瘤細(xì)胞分子生物學(xué)，腫瘤病理學(xué)以及腫瘤影像診斷、腫瘤外科治療、化學(xué)治療、放射治療、介入治療、生物治療和中西醫(yī)結(jié)合治療腫瘤等各分支學(xué)科，旨在促進(jìn)國(guó)內(nèi)外學(xué)術(shù)交流，提高我國(guó)癌癥研究與癌癥治療水平。
Chinese Journal of Cancer Research
- Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)
- Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020
- Mitochondrial malic enzyme 2 promotes breast cancer metastasis via stabilizing HIF-1α under hypoxia
- Psychosomatic symptoms affect radiotherapy setup errors in early breast cancer patients
- Reappraise role of lymph node status in patterns of recurrence following curative resection of gastric adenocarcinoma
- Pain threshold,anxiety and other factors affect intensity of postoperative pain in gastric cancer patients:A prospective cohort study
- A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers
- Profiling of hepatocellular carcinoma neoantigens reveals immune microenvironment and clonal evolution related patterns
- Prognostic value of a modified Immunoscore in patients with stage I-III resectable colon cancer
- Single-cell DNA methylome analysis of circulating tumor cells
- Phase 1 studies comparing safety,tolerability,pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
- Current evidence and challenges of systematic therapies for adult recurrent glioblastoma:Results from clinical trials